论文部分内容阅读
目的评估爱活尿通对良性前列腺增生症排尿困难等症状的有效性和安全性。方法进行为期12周的开放性、多中心、自身前后对照的临床研究。100例以国际前列腺症状评分(IPSS),最大尿流率(Qmax),经腹B超测定膀胱残余尿量(Ru)以及经腹B超测定前列腺体积(V)为主要评价指标;生活质量评分(QoL),平均尿流率(Qave)或前列腺直肠指诊为次要评价指标。对每位患者随访12周后观察治疗效果和药物安全性。结果100例患者均完成临床观察。治疗12周后显效36例(36%),有效53例(53%),改善9例(9%),无效2例(2%),总有效率89%。只有1例患者服药后出现头晕、乏力、走路不稳,3天后自行缓解,其余患者未出现与药物有关的不良反应。结论爱活尿通治疗良性前列腺增生症安全、有效,患者依从性高。
Objective To evaluate the effectiveness and safety of Alopecia acuminata on symptoms of dysuria in benign prostatic hyperplasia. Methods A 12-week open, multicenter, self-controlled clinical study was performed. One hundred cases were evaluated by International Prostate Symptom Score (IPSS), Maximal Urine Flow Rate (Qmax), Transurethral B-mode ultrasonography (Ru) and Trans-abdominal ultrasonography (Prostate volume) (QoL), average flow rate (Qave) or prostate digital rectal examination as a secondary evaluation. Each patient was followed up for 12 weeks to observe the therapeutic effect and drug safety. Results 100 patients completed the clinical observation. After 12 weeks of treatment, 36 cases (36%) were effective, 53 cases (53%) were effective, 9 cases (9%) were improved, 2 cases (2%) were ineffective and the total effective rate was 89%. Only one patient dizziness, fatigue, walking instability after taking medication, relieve itself after 3 days, the remaining patients did not appear drug-related adverse reactions. Conclusion Love live urinary tract treatment of benign prostatic hyperplasia is safe and effective, patients with high compliance.